Breaking News Instant updates and real-time market news.

MO

Altria Group

$49.00

0.17 (0.35%)

, BTI

British American Tobacco

$38.15

-0.21 (-0.55%)

16:47
11/22/19
11/22
16:47
11/22/19
16:47

POTUS in favor of raising minimum vaping age to 21, MarketWatch says

U.S. President Donald Trump is in favor of raising the minimum age for purchasing nicotine vaping products to 21 years old from 18, MarketWatch's Jaimy Lee reports, citing comments made during a meeting Friday that was attended by the CEOs of some of the nation's biggest vaping companies, including Altria Group (MO), Juul Labs, and Njoy. The administration appears to be backing off a plan, announced in September, to ban most flavors of e-cigarettes, despite worries from health organizations and physicians groups, Lee says. Trump added during the discussion forum that he has concerns with "prohibition" since illegal vape products bought on the black market could be especially unsafe compared with ones sold in a regulated market, the author notes.Other publicly traded companies in the tobacco space include British American Tobacco (BTI), Imperial Brands (IMBBY) and Philip Morris (PM). Reference Link

MO

Altria Group

$49.00

0.17 (0.35%)

BTI

British American Tobacco

$38.15

-0.21 (-0.55%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$82.39

-1.08 (-1.29%)

  • 30

    Jan

MO Altria Group
$49.00

0.17 (0.35%)

11/19/19
STFL
11/19/19
NO CHANGE
STFL
Buy
Altria slide on Juul lawsuit news 'irrational and illogical,' says Stifel
Stifel analyst Christopher Growe said he views Altria's 2% pullback on news that New York's Attorney General is filing a lawsuit against Juul as "both irrational and illogical" given the fact that Altria does not share in this legal liability. Additionally, the value of Juul has already been written down to $8.3B and he believes the actual value embedded in Altria's nearly $90B in equity value is "only a fraction" of that amount. Growe, who thinks today's volatility in the price of Altria shares is "unwarranted" and presents a strong buying opportunity, keeps a Buy rating on the stock.
10/18/19
10/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Neutral from Sell at Citi with analyst Adam Spielman saying he now expects "less bad" cigarette volumes next year. 2. Snap (SNAP) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post saying the stock has sold off despite "solid" industry and advertising spend channel checks. 3. Chipotle (CMG) upgraded to Neutral from Underperform at BofA/Merrill with analyst Gregory Francort saying he expects the company to generate better comps and margins over the near term given its "strong" sales momentum and normalizing avocado prices, even though he is "struggling" with the valuation on the stock. 4. Republic Services (RSG) upgraded to Buy from Neutral at BofA/Merrill with analyst Michael Feniger calling the stock "a more balanced way" to gain exposure to the theme of higher disposal pricing than peer Waste Management (WM), which he downgraded this morning. 5. Waste Connections (WCN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Sean Eastman saying he expects Waste Connections to report an in-line Q3, and sees 2019 guidance remaining intact. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/19
SBSH
10/18/19
UPGRADE
Target $46
SBSH
Neutral
Citi upgrades Altria to Neutral on 'less bad' cigarette volume outlook
Citi analyst Adam Spielman upgraded Altria Group to Neutral from Sell with a price target of $46, up from $45. The stock closed Thursday up 77c to $44.28. The analyst now expects "less bad" cigarette volumes next year. Electronic vapor usage will fall due to the negative publicity around vaping and the imminent flavor ban, which will help cigarettes, Spielman tells investors in a research note. Further, with Altria shares below his price target, the analyst no longer thinks the stock looks expensive relative to overseas peers. With that said, Spielman still expects the short-term news flow, both on FDA regulation and earnings, "to be difficult."
11/22/19
PIPR
11/22/19
NO CHANGE
Target $52
PIPR
Neutral
Altria checks show 'promising' prospects for iQOS, says Piper Jaffray
Piper Jaffray analyst Michael Lavery says that after his channel checks of the Atlanta iQOS test market, he believes prospects for its U.S. launch are "promising." Altria Group has many tools to responsibly market iQOS, making it visible to a broad audience of adult smokers without attracting underage users, Lavery tells investors in a research note. He believes believe iQOS could benefit as a vapor-free, smoke-free option for consumers. The analyst raised his price target for Altria shares to $52 from $49 and keeps a Neutral rating on the name.
BTI British American Tobacco
$38.15

-0.21 (-0.55%)

09/12/19
SBSH
09/12/19
NO CHANGE
SBSH
E-vapor regulation to hit Juul hard, 'odd time' for merger talks, says Citi
The Trump Administration said yesterday that it will "clear" the market of all non-tobacco flavored e-vapor products, including mint and menthol, Citi analyst Adam Spielman tells investors in a research note. The analyst had hoped the rules would have little impact on Juul as it has stopped supplying fruit flavors to physical stores. However, Trump's proposal is likely to hit Juul hard, as about three-quarter of its volume is in mint, says Spielman. Further, he believes at least half of British American Tobacco's (BTI) and IImperial Brands' (IMBBY) e-vapor volumes in the U.S. will be banned under the new definition. This all reinforces that this is an "odd time" for Philip Morris (PM) and Altria Group (MO) to be in merger talks, contends Spielman. The analyst, who doubts Trump's announcement will affect the talks between the companies, says the future of tobacco regulation in the U.S. is unclear currently. "We can only assume the companies have chosen to talk now because they are very confident about the outcomes. We, by contrast, see plenty of risk," writes Spielman.
08/28/19
JPMS
08/28/19
NO CHANGE
JPMS
Neutral
Philip Morris selloff on Altria merger talks overdone, says JPMorgan
JPMorgan analyst Celine Pannuti views the selloff in shares of Philip Morris (PM) following confirmation of the company's merger talks with Altria Group (MO) as overdone. The deal leads to value accretion at no premium and U.S. regulatory risks are already embedded in the sector de-rating, Pannuti tells investors in a research note. The analyst also sees the weakness in British American Tobacco (BTI) shares as a buying opportunity. The consideration of a merger between Philip Morris and Altria is a vote of confidence in the U.S. combustibles profit pool, contrary to current market sentiment, says Pannuti. The analyst keeps a Neutral rating on Philip Morris with an $86 price target.
08/27/19
SBSH
08/27/19
NO CHANGE
SBSH
Citi sees no antitrust reason to stop Philip Morris, Altria deal
Citi analyst Adam Spielman is surprised by the merger talks between Philip Morris (MO) and Altria Group (MO) but feels the deal is likely to go ahead as he sees no antitrust reason to stop it. With the combined company likely a stronger competitor, the potential deal is not a positive for both British American Tobacco (BTI) and Imperial Brands (IMBBY), Spielman tells investors in a research note.
07/16/19
WELS
07/16/19
NO CHANGE
WELS
Wells says Nielsen restatement could be positive for Monster, tobacco stocks
Wells Fargo analyst Bonnie Herzog noted that Nielsen (NLSN) just announced that it will restate data to address serious issues with its calculation methodology in the convenience store channel related to projections it applied to independent c-stores. The restated data, to be released on August 20, is expected to improve cigarette and energy drink trends and she views this as a positive for tobacco stocks and Monster Beverage (MNST). Publicly traded companies in the tobacco space include Altria Group (MO), British American Tobacco (BTI) and Philip Morris (PM).
IMBBY Imperial Brands
$0.00

(0.00%)

05/28/19
SBSH
05/28/19
NO CHANGE
SBSH
Cigarette data from Nielsen 'dire,' industry data also 'very bad,' says Citi
Citi analyst Adam Spielman noted that Nielsen reported earlier today that cigarette industry volumes fell 11.2% in the four weeks ended May 18, noting that shares of Altria (MO), British American Tobacco (BTI) and Imperial (IMBBY) all fell following the "dire" data. Volumes in MSAi, the industry database that he regards as much more reliable than Nielsen, were down 6.4% in the same period, which Spielman said "is still a very bad figure, but it is a lot, lot better than the Nielsen one." Looking ahead, the analyst said he expects "gradually less bad" volumes in Nielsen in the rest of the year, though he noted that Altria has said it expects industry volumes to fall about 4%-5% this year and he forecasts a decline of about 6%. In late afternoon trading, Altria shares are down 4.5%, British American has declined over 4% and Philip Morris (PM) is down 5%.
03/28/19
SBSH
03/28/19
UPGRADE
SBSH
Buy
Imperial Brands upgraded to Buy from Neutral at Citi
Citi analyst Adam Spielman upgraded Imperial Brands to Buy from Neutral and raised his price target for the shares to GBP 30 from GBP 27. The analyst believes organic revenue growth for tobacco companies will pick up this year as sales of next generation products accelerate. Further, the regulatory threat will probably move away from cigarettes, Spielman tells investors in a research note. He thinks an even greater focus on e-vapor cigarettes could be positive for both British American Tobacco and Imperial Brands.
PM Philip Morris
$82.39

-1.08 (-1.29%)

10/01/19
BOFA
10/01/19
UPGRADE
BOFA
Buy
Philip Morris upgraded to Buy from Neutral at BofA/Merrill
10/01/19
10/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ericsson (ERIC) upgraded to Buy from Hold at Canaccord with analyst Michael Walkley saying since the Q2 earnings report, Ericsson has announced deals with Nex-Tech, RINA, and KDDI, demonstrating continuing 5G momentum. 2. VMware (VMW) upgraded to Outperform from Market Perform at Wells Fargo with analyst Philip Winslow saying investors have been concerned that growing interest in deploying containerized applications into Kubernetes-centric environments will eventually reduce customer demand for VMware's virtualization-centric product portfolio. 3. Tradeweb Markets (TW) upgraded to Overweight from Equal Weight at Barclays with analyst Jeremy Campbell saying recent weakness in the shares "seems largely technical," which presents an "attractive upside opportunity." 4. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underperform at BofA/Merrill with analyst Christopher Carey saying the bar on the company's earnings consensus may be "too low." 5. Philip Morris (PM) upgraded to Buy from Neutral at BofA/Merrill with analyst Lisa Lewandowski citing the suspended merger discussions with Altria (MO) amid the heightened risk for U.S. vaping category following reports of lung health concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/19
BOFA
10/01/19
UPGRADE
Target $96
BOFA
Buy
Philip Morris upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Lisa Lewandowski upgraded Philip Morris (PM) to Buy with a price target of $96 after the suspended merger discussions with Altria (MO) amid the heightened risk for U.S. vaping category following reports of lung health concerns. The analyst notes that the whole industry may be impacted by uncertainty around vaping, but she sees Philip Morris rising above the "noise" due to its lack of vaping exposure, strong underlying fundamentals, and potential for offering alternatives to vaping products.
09/26/19
WELS
09/26/19
NO CHANGE
WELS
Wells Fargo not surprised Philip Morris, Altria Group ended merger talks
Wells Fargo analyst Bonnie Herzog says that while she is dismayed by the announcement that Philip Morris (PM) and Altria (MO) have ended merger talks, she is not all that surprised given the length of negotiations and the litany of negative FDA/health headlines throughout. The analyst expects the stocks to trade up sharply since "clearly the market wasn't in favor of this combination." Herzog adds that it appears to her the talks fell apart over JUUL and the companies announced they have agreed to focus on launching iQOS in the U.S. "as part of their mutual interest to achieve a smoke free future." The analyst continues to believe Philip Morris/Altria have a competitive advantage, especially in this environment, with iQOS. She continues to "strongly recommend" both stocks, with Philip Morris remaining her top stock pick.

TODAY'S FREE FLY STORIES

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

07:19
12/09/19
12/09
07:19
12/09/19
07:19
Conference/Events
Autolus Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

SPCE

Virgin Galactic

$7.28

0.07 (0.97%)

07:17
12/09/19
12/09
07:17
12/09/19
07:17
Initiation
Virgin Galactic initiated  »

Morgan Stanley cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

TCBI

Texas Capital

$57.82

0.76 (1.33%)

, IBTX

Independent Bank

$59.23

1 (1.72%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Hot Stocks
Independent Bank, Texas Capital Bancshares enter $5.5B all-stock merger »

Texas Capital Bancshares…

TCBI

Texas Capital

$57.82

0.76 (1.33%)

IBTX

Independent Bank

$59.23

1 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

$41.25

0.11 (0.27%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Recommendations
Zai Lab analyst commentary  »

Citi opens 'positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$27.45

0.02 (0.07%)

07:14
12/09/19
12/09
07:14
12/09/19
07:14
Hot Stocks
Pattern Energy announces expiration of 'Go-Shop Period' »

Pattern Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$171.49

7.13 (4.34%)

07:12
12/09/19
12/09
07:12
12/09/19
07:12
Downgrade
3M rating change  »

Citi downgrades 3M to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

FTV

Fortive

$72.86

0.5 (0.69%)

, MMM

3M

$171.49

7.13 (4.34%)

07:11
12/09/19
12/09
07:11
12/09/19
07:11
Upgrade
Fortive, 3M rating change  »

Citi upgrades Fortive to…

FTV

Fortive

$72.86

0.5 (0.69%)

MMM

3M

$171.49

7.13 (4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

ORAN

Orange SA

$15.02

-0.055 (-0.36%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Downgrade
Orange SA rating change  »

Orange SA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMDA

Kamada

$7.36

-0.025 (-0.34%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Hot Stocks
Kamada enters into binding term sheet, sees product adding $8M-$10M in revenue »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Hot Stocks
Canadian Solar authorizes $150M share repurchase program »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETNB

89bio

$28.38

0.86 (3.13%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONG

Akazoo

$5.40

-0.12 (-2.17%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Earnings
Akazoo reports Q3 EPS EUR0.03 vs, EUR0.02 last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$15.03

-0.01 (-0.07%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Upgrade
Eagle Point Credit rating change  »

Eagle Point Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$122.36

1.6 (1.32%)

07:07
12/09/19
12/09
07:07
12/09/19
07:07
Conference/Events
Texas Instruments management to meet with UBS »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 16

    Dec

KALV

KalVista

$14.36

0.25 (1.77%)

, MRK

Merck

$88.84

0.09 (0.10%)

07:06
12/09/19
12/09
07:06
12/09/19
07:06
Hot Stocks
KalVista says KVD001 does not meet primary endpoint »

KalVista Pharmaceuticals…

KALV

KalVista

$14.36

0.25 (1.77%)

MRK

Merck

$88.84

0.09 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

VTNR

Vertex Energy

$1.59

(0.00%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Initiation
Vertex Energy initiated  »

Vertex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.20

-0.01 (-0.03%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Conference/Events
AT&T management to meet with UBS »

Dinner Meeting with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

NOW

ServiceNow

$272.19

-0.94 (-0.34%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Conference/Events
ServiceNow management to meet with UBS »

Dinner Meeting with Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Hot Stocks
Rocket Pharmaceuticals announces preliminary data from RP-L201 Phase 1/2 trial »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Recommendations
Agios Pharmaceuticals analyst commentary  »

Cantor sees Agios trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:01
12/09/19
12/09
07:01
12/09/19
07:01
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

CI

Cigna

$198.96

3.44 (1.76%)

07:00
12/09/19
12/09
07:00
12/09/19
07:00
Conference/Events
Cigna management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 06

    Feb

AMAT

Applied Materials

$56.60

0.77 (1.38%)

06:59
12/09/19
12/09
06:59
12/09/19
06:59
Conference/Events
Applied Materials management to meet with UBS »

Breakfast Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CGC

Canopy Growth

$18.65

0.07 (0.38%)

, STZ

Constellation Brands

$183.60

1.13 (0.62%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Recommendations
Cantor sees over 66% chance of Constellation bidding for Canopy Growth »

Cantor Fitzgerald analyst…

CGC

Canopy Growth

$18.65

0.07 (0.38%)

STZ

Constellation Brands

$183.60

1.13 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

MTG

MGIC Investment

$14.10

-0.03 (-0.21%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Hot Stocks
MGIC Investment issues November operating statistics »

MGIC Investment issued an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.